Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up
No Thumbnail Available
Identifiers
Date
2021-11-20
Authors
Strauss, S. J.
Frezza, A. M.
Abecassis, N.
Bajpai, J.
Bauer, S.
Biagini, R.
Bielack, S.
Blay, J. Y.
Bolle, S.
Bonvalot, S.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
Abstract
Primary bone sarcomas (BSs) account for <0.2% of malignant neoplasms across all ages.1 The overall incidence rate ranges between 0.8 and 0.9 cases per 100 000/year, with single BS types having no more than 0.3 incident cases per 100 000/year. Osteosarcoma and Ewing sarcoma (ES) have a relatively high incidence in the second decade of life, whereas conventional chondrosarcomas are more common in older age.2
Description
MeSH Terms
Sarcoma, Ewing
Incidence
Osteosarcoma
Chondrosarcoma
Incidence
Osteosarcoma
Chondrosarcoma
DeCS Terms
Incidencia
Huesos
Sarcoma
Sarcoma de Ewing
Osteosarcoma
Vida
Neoplasias
Condrosarcoma
Huesos
Sarcoma
Sarcoma de Ewing
Osteosarcoma
Vida
Neoplasias
Condrosarcoma
CIE Terms
Keywords
bone sarcoma, clinical practice guideline, diagnosis, treatment, follow-up, management, Localized ewing sarcoma, Giant-cell tumor, Malignant fibrous histiocytoma, High-grade osteosarcoma, High-dose ifosfamide, Open-label, Phase-ii, Neoadjuvant chemotherapy, Prognostic-factors, Muramyl tripeptide
Citation
Strauss SJ, Frezza AM, Abecassis N, Bajpai J, Bauer S, Biagini R, et al. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021 Dec;32(12):1520-1536.